Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506358 | 0.83 | MTOR (0.49) | PARP1LCKBRD4KDM4EALDH1A1 | |
| SCHEMBL1233265 | 0.83 | MTOR (0.49) | PARP1LCKBRD4KDM4EALDH1A1 | |
| SCHEMBL498268 | 0.81 | TSHR (0.52) | KDM4EALDH1A1SMN1; SMN2HSD17B10CA1 | |
| SCHEMBL29503140 | 0.80 | PRSS1 (0.61) | PARP1LCKALDH1A1SMN1; SMN2PRSS1 | |
| SCHEMBL1002832 | 0.80 | PRSS1 (0.61) | PARP1LCKALDH1A1SMN1; SMN2PRSS1 | |
| SCHEMBL10249696 | 0.80 | PARP1 (0.58) | PARP1LCKBRD4KDM4EALDH1A1 | |
| SCHEMBL3561298 | 0.79 | CES2 (0.37) | PARP1ALDH1A1SMN1; SMN2HSD17B10TSHR | |
| SCHEMBL9541786 | 0.78 | PARP1 (0.52) | PARP1LCKBRD4KDM4EALDH1A1 | |
| SCHEMBL2128609 | 0.78 | PARP1 (0.52) | PARP1LCKBRD4KDM4EALDH1A1 | |
| SCHEMBL15866552 | 0.78 | SMN1; SMN2 (0.63) | ALDH1A1SMN1; SMN2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350311-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | MADRIGAL PHARMACEUTICALS INC (US) | 2013-12-25 | — | — | EP | claimed |
| CN-115286605-B | Method for synthesizing isochromanone compounds based on carbon monoxide gas or carbon monoxide alternative source | 武汉大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-113372184-B | Method for synthesizing C-N axis chiral phenanthridinone compound based on chiral transfer strategy | 武汉大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-115286605-A | Method for synthesizing isochromanone compounds based on carbon monoxide gas or carbon monoxide substitute source | 武汉大学 | 2022-11-04 | — | — | CN | disclosed |
| CN-113372184-A | Method for synthesizing C-N axis chiral phenanthridinone compound based on chiral transfer strategy | 武汉大学 | 2021-09-10 | — | — | CN | disclosed |
| EP-2417125-B1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-09-09 | — | — | EP | disclosed |
| US-8772280-B2 | N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as MPS1 kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-08 | — | — | US | disclosed |
| EP-2350311-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | MADRIGAL PHARMACEUTICALS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120130144-A1 | TREATMENT OF LUNG CANCER WITH A NITROBENZAMIDE COMPOUND IN COMBINATION WITH A GROWTH FACTOR INHIBITOR | BIPAR SCIENCES, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| EP-2417125-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-02-15 | — | — | EP | disclosed |
| US-20120004260-A1 | INHIBITION OF FATTY ACID SYNTHESIS BY IODO-NITROBENZAMIDE COMPOUNDS AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-7820144-B2 | Receptor selective cannabimimetic aminoalkylindoles | UNIVERSITY OF CONNECTICUT (US) | 2010-10-26 | — | — | US | disclosed |
| WO-2010108921-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010056506-A1 | DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20070243134-A1 | Receptor Selective Cannabimimetic Aminoalkylindoles | CONNECTICUT, UNIVERSITY OF | 2007-10-18 | — | — | US | disclosed |
| US-20070243134-A1 | Receptor Selective Cannabimimetic Aminoalkylindoles | CONNECTICUT, UNIVERSITY OF | 2007-10-18 | — | — | US | disclosed |
| US-7173027-B2 | Receptor selective cannabimimetic aminoalkylindoles | UNIVERSITY OF CONNECTICUT (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173027-B2 | Receptor selective cannabimimetic aminoalkylindoles | UNIVERSITY OF CONNECTICUT (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070243134-A1 | Receptor Selective Cannabimimetic Aminoalkylindoles | CNR2, CNR1, GPR18 | PARP1 2334/4885LCK 702/4885BRD4 257/4885 |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, MOGAT2 | PARP1 3867/4885LCK 3399/4885BRD4 1645/4885 |
| US-20120130144-A1 | TREATMENT OF LUNG CANCER WITH A NITROBENZAMIDE COMPOUND IN COMBINATION WITH A GROWTH FACTOR INHIBITOR | PARP2, PARP12, PARP15 | PARP1 4/4885LCK 1231/4885BRD4 68/4885 |
| US-20120004260-A1 | INHIBITION OF FATTY ACID SYNTHESIS BY IODO-NITROBENZAMIDE COMPOUNDS AND METHODS OF TREATMENT THEREOF | FASN, PARP12, PARP2 | PARP1 15/4885LCK 1457/4885BRD4 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.